Rigel Recovers On 2013 Hope For Its Rheumatoid Arthritis Drug Pharmaceutical Processing R548 - the JAK3 inhibitor intended to be used to inhibit organ transplant rejection, now entering phase I trials. Shares of Rigel Pharmaceuticals may remain propped up on the hope that phase III trials for fostamatinib provide better data in 2013 ... |
